the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

716

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

November 1, 2024

Conditions
Ischemic StrokeAlteplase Adverse Reaction
Interventions
DRUG

Alteplase

Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit

DRUG

Alteplase

Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit

Trial Locations (1)

33511

RECRUITING

Kafr Elsheikh University Hospital, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER